Nat Commun:复发性尿路感染中大肠杆菌ST131系群体动态研究

2019-08-26 AlexYang MedSci原创

复发性尿路感染(rUTIs)是极度常见的,且大约25%的女性在她们的起始感染后1年内经历复发。大肠杆菌ST131是一种具有全球多种耐药性的抗性克隆,并且与rUTI的高发病率相关。最近,有研究人员在一名患有rUTI的女性中展示了ST131群体动态情况,时间从1970s开始,动态展示时间为5年。研究人员通过使用全基因组测序方法,鉴定了一个与rUTI和粪便菌群持久性有关的土著无性菌系(P1A),为rUT

复发性尿路感染(rUTIs)是极度常见的,且大约25%的女性在她们的起始感染后1年内经历复发。大肠杆菌ST131是一种具有全球多种耐药性的抗性克隆,并且与rUTI的高发病率相关。

最近,有研究人员在一名患有rUTI的女性中展示了ST131群体动态情况,时间从1970s开始,动态展示时间为5年。研究人员通过使用全基因组测序方法,鉴定了一个与rUTI和粪便菌群持久性有关的土著无性菌系(P1A),为rUTI在肠道内的存在提供了令人信服的证据。研究人员同样展示了P1A菌系具有大量的质粒多态性,从而导致了不同抗生素抗性共存现象,以及尽管经常治疗仍旧存在敏感肠内隔离区。

最后,研究人员指出,他们的纵向研究为单个个体内的克隆谱系提供了独特的全面基因组分析,并提出了一种可快速适应波动的抗生素治疗的广泛性耐药机制。

原始出处:

Brian M. Forde, Leah W. Roberts, Minh-Duy Phan et al. Population dynamics of an Escherichia coli ST131 lineage during recurrent urinary tract infection. Nat Commun. 13 Aug 2019

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1883842, encodeId=567418838424b, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Thu Dec 12 19:06:00 CST 2019, time=2019-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909784, encodeId=d0891909e84c9, content=<a href='/topic/show?id=8f1f42518d8' target=_blank style='color:#2F92EE;'>#复发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42518, encryptionId=8f1f42518d8, topicName=复发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Fri May 22 04:06:00 CST 2020, time=2020-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087578, encodeId=0324208e5787f, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Wed Jul 22 08:06:00 CST 2020, time=2020-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1717015, encodeId=9d501e1701567, content=<a href='/topic/show?id=f8a98002eb1' target=_blank style='color:#2F92EE;'>#群体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80027, encryptionId=f8a98002eb1, topicName=群体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c0832353243, createdName=xjy13, createdTime=Tue May 05 09:06:00 CST 2020, time=2020-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1339986, encodeId=12a8133998671, content=<a href='/topic/show?id=e6624383eaf' target=_blank style='color:#2F92EE;'>#大肠杆菌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43837, encryptionId=e6624383eaf, topicName=大肠杆菌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0d342500153, createdName=12498bf3m25暂无昵称, createdTime=Wed Aug 28 11:06:00 CST 2019, time=2019-08-28, status=1, ipAttribution=)]
    2019-12-12 liye789132251
  2. [GetPortalCommentsPageByObjectIdResponse(id=1883842, encodeId=567418838424b, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Thu Dec 12 19:06:00 CST 2019, time=2019-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909784, encodeId=d0891909e84c9, content=<a href='/topic/show?id=8f1f42518d8' target=_blank style='color:#2F92EE;'>#复发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42518, encryptionId=8f1f42518d8, topicName=复发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Fri May 22 04:06:00 CST 2020, time=2020-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087578, encodeId=0324208e5787f, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Wed Jul 22 08:06:00 CST 2020, time=2020-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1717015, encodeId=9d501e1701567, content=<a href='/topic/show?id=f8a98002eb1' target=_blank style='color:#2F92EE;'>#群体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80027, encryptionId=f8a98002eb1, topicName=群体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c0832353243, createdName=xjy13, createdTime=Tue May 05 09:06:00 CST 2020, time=2020-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1339986, encodeId=12a8133998671, content=<a href='/topic/show?id=e6624383eaf' target=_blank style='color:#2F92EE;'>#大肠杆菌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43837, encryptionId=e6624383eaf, topicName=大肠杆菌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0d342500153, createdName=12498bf3m25暂无昵称, createdTime=Wed Aug 28 11:06:00 CST 2019, time=2019-08-28, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1883842, encodeId=567418838424b, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Thu Dec 12 19:06:00 CST 2019, time=2019-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909784, encodeId=d0891909e84c9, content=<a href='/topic/show?id=8f1f42518d8' target=_blank style='color:#2F92EE;'>#复发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42518, encryptionId=8f1f42518d8, topicName=复发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Fri May 22 04:06:00 CST 2020, time=2020-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087578, encodeId=0324208e5787f, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Wed Jul 22 08:06:00 CST 2020, time=2020-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1717015, encodeId=9d501e1701567, content=<a href='/topic/show?id=f8a98002eb1' target=_blank style='color:#2F92EE;'>#群体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80027, encryptionId=f8a98002eb1, topicName=群体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c0832353243, createdName=xjy13, createdTime=Tue May 05 09:06:00 CST 2020, time=2020-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1339986, encodeId=12a8133998671, content=<a href='/topic/show?id=e6624383eaf' target=_blank style='color:#2F92EE;'>#大肠杆菌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43837, encryptionId=e6624383eaf, topicName=大肠杆菌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0d342500153, createdName=12498bf3m25暂无昵称, createdTime=Wed Aug 28 11:06:00 CST 2019, time=2019-08-28, status=1, ipAttribution=)]
    2020-07-22 liuli5079
  4. [GetPortalCommentsPageByObjectIdResponse(id=1883842, encodeId=567418838424b, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Thu Dec 12 19:06:00 CST 2019, time=2019-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909784, encodeId=d0891909e84c9, content=<a href='/topic/show?id=8f1f42518d8' target=_blank style='color:#2F92EE;'>#复发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42518, encryptionId=8f1f42518d8, topicName=复发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Fri May 22 04:06:00 CST 2020, time=2020-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087578, encodeId=0324208e5787f, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Wed Jul 22 08:06:00 CST 2020, time=2020-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1717015, encodeId=9d501e1701567, content=<a href='/topic/show?id=f8a98002eb1' target=_blank style='color:#2F92EE;'>#群体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80027, encryptionId=f8a98002eb1, topicName=群体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c0832353243, createdName=xjy13, createdTime=Tue May 05 09:06:00 CST 2020, time=2020-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1339986, encodeId=12a8133998671, content=<a href='/topic/show?id=e6624383eaf' target=_blank style='color:#2F92EE;'>#大肠杆菌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43837, encryptionId=e6624383eaf, topicName=大肠杆菌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0d342500153, createdName=12498bf3m25暂无昵称, createdTime=Wed Aug 28 11:06:00 CST 2019, time=2019-08-28, status=1, ipAttribution=)]
    2020-05-05 xjy13
  5. [GetPortalCommentsPageByObjectIdResponse(id=1883842, encodeId=567418838424b, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Thu Dec 12 19:06:00 CST 2019, time=2019-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909784, encodeId=d0891909e84c9, content=<a href='/topic/show?id=8f1f42518d8' target=_blank style='color:#2F92EE;'>#复发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42518, encryptionId=8f1f42518d8, topicName=复发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Fri May 22 04:06:00 CST 2020, time=2020-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087578, encodeId=0324208e5787f, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Wed Jul 22 08:06:00 CST 2020, time=2020-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1717015, encodeId=9d501e1701567, content=<a href='/topic/show?id=f8a98002eb1' target=_blank style='color:#2F92EE;'>#群体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80027, encryptionId=f8a98002eb1, topicName=群体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c0832353243, createdName=xjy13, createdTime=Tue May 05 09:06:00 CST 2020, time=2020-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1339986, encodeId=12a8133998671, content=<a href='/topic/show?id=e6624383eaf' target=_blank style='color:#2F92EE;'>#大肠杆菌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43837, encryptionId=e6624383eaf, topicName=大肠杆菌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0d342500153, createdName=12498bf3m25暂无昵称, createdTime=Wed Aug 28 11:06:00 CST 2019, time=2019-08-28, status=1, ipAttribution=)]

相关资讯

BMJ:老年尿路感染患者抗生素治疗与预后

研究认为,65岁以上老年泌尿系感染患者应及时接受抗生素治疗,可显著降低血液感染以及不良预后风险

JAMA Intern Med:减少复发性尿路感染反复 多喝水能少吃药?!

急性非复杂性膀胱炎是女性最常见的感染性疾病之一,终生的患病风险超过50%。有观点认为,对细菌尿进行稀释和冲洗有益,常建议复发性膀胱炎女性患者在抗生素干预前,增加水合作用。然而,考察水合作用与尿路感染(UTI)风险相关性的研究很少,且不足以令人信服。

2 型糖尿病伴发复发性尿路感染一例

患者49岁,男,因“口渴、多饮、多尿14a,尿频、尿急、尿痛2个月”于2014年7月17日入院。14a前出现口渴、多饮、多尿,当地医院测随机血糖20mmol/L,诊为“2型糖尿病”,不规则口服“消渴丸、二甲双胍”治疗,偶测空腹血糖,波动于13~14mmol/L。1a前出现双足背麻木,呈对称性,无双足疼痛、蚁走感,无腹泻与便秘交替,未治疗。

Diabetes Obes Metab:SGLT2抑制剂与生殖器真菌感染和尿路感染的风险

由此可见,在老年女性和男性中使用SGLT2抑制剂与30天内生殖器真菌感染的风险增加有关,而与UTI风险增加无关。来自现实环境的这些发现提供了SGLT2抑制剂存在潜在危害的证据。

高龄患者尿路感染 药物治疗注意什么?

患者,男,83岁,因“进行性排尿困难2年,加重3周”入院。

Obstet Gynecol:良性妇科疾病或盆腔重建手术进行子宫切除术后尿路感染分析

由此可见,包括盆腔重建手术在内的子宫切除术后UTI发生率有很大差异,可以使用基于术前数据的模型来解释这些变化。